Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

Xu, Pengpeng; Fu, Di; Li, Jianyong; Hu, Jianda; Wang, Xin; Zhou, Jianfeng; Yu, Hao; Zhao, Xia; Huang, Yan‐Jiun; Jiang, Libin; Liu, Feng; Chen, Zhuo-Wen; Zeng, Qingshu; Chen, Jieping; Fang, Meiyun; Ma, Jun; Liu, Ting; Song, Yongping; Kang, Yu; Li, Yan; Qiu, Lugui; Chen, Xiequn; Gu, Jian; Yan, Jinsong; Hou, Mingxiao; Huang, Huizhen; Wang, Li; Cheng, Shu; Shen, Yang; Xiong, Hui; Chen, Sai‐Juan; Zhao, Wei‐Li

doi:10.1016/s2352-3026(19)30051-1

Cited by 35 publications

(44 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this phase II study, we showed that CR-CHOP was effective in firstline therapy of elderly patients with newly diagnosed DLBCL. After six cycles of CR-CHOP, the complete response rate was higher than those of previous reports in Western countries (71-76%) [2,3] and in China (72%) [13], all of which contained low-risk IPI patients. In a recent phase I study of valproate plus R-CHOP in newly diagnosed DLBCL (26% of the patients had intermediatehigh or high-risk IPI), improvement of clinical outcome has been achieved, with PFS of 84.7% and OS of 96.8% at 2 years [18].…”

Section: Discussioncontrasting

confidence: 68%

See 1 more Smart Citation

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied to treat DLBCL. This study aimed to evaluate efficacy and safety of oral HDACI tucidinostat (formerly known as chidamide) plus R-CHOP (CR-CHOP) in elderly patients with newly diagnosed DLBCL (International Prognostic Index ≥ 2). Results Among 49 patients, the complete response rate was 86%, with overall response rate achieving 94%. The 2-year progression survival (PFS) and overall survival (OS) rates were 68% (95% CI 52–79) and 83% (95% CI 68–91). Comparing with historical control (NCT01852435), the 2-year PFS and OS rates of double-expressor lymphoma phenotype (DEL) were improved, and negative prognostic effect of histone acetyltransferases CREBBP/EP300 mutations was also mitigated by CR-CHOP. Grade 3–4 neutropenia was reported in 171, grade 3–4 thrombocytopenia in 27, and grade 3 anemia in 11 of 283 cycles. No grade 4 non-hematological adverse event was reported. Conclusion CR-CHOP is effective and safe in elderly patients with newly diagnosed DLBCL. Relevance of DEL phenotype and molecular biomarkers on CR-CHOP response warrants further investigation in DLBCL. Trial registration ClinicalTrial.gov, NCT02753647. Registered on April 28, 2016.

show abstract

Section: Discussioncontrasting

confidence: 68%

“…In a SAKK 38/07 prospective cohort, CREBBP mutation is an independent prognostic factor in DLBCL [11]. Elderly DLBCL patients are generally more frequently categorized into those high-risk groups [12,13], providing clues for searching potential targeted therapeutic strategies.…”

mentioning

confidence: 99%

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Eventually, 26 qualified RCTs were included for trial- and treatment arm-level analyses (Table 1 ) [ 1 – 4 , 13 – 19 , 22 – 36 ]. According to the purposes of each trial, 26 RCTs were classified into 5 subgroups: (1) four RCTs (15%) compared R-CHOP (like) with CHOP (like) [ 1 – 4 ]; (2) ten (38%) RCTs compared R-CHOP (like) with rituximab+intensified/de-escalated chemotherapy [ 13 , 15 – 17 , 22 , 23 , 25 – 27 , 31 ]; (3) nine (35%) investigated maintenance or consolidation therapy [ 3 , 14 , 18 , 23 , 24 , 28 – 30 , 32 ]; (4) three (12%) focused on R-CHOP+novel targeted therapy [ 19 , 34 , 35 ]; (5) two (8%) investigated the novel use of anti-CD20 monoclonal antibody [ 33 , 36 ]. Of note, the two-stage randomized trial ECOG4494/CALGB9793 [ 3 ] and the 2 × 2 factorial randomized trial DLCL04 [ 23 ] were classified into 2 subgroups according to the respective research questions.…”

Section: Methodsmentioning

confidence: 99%

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review

et al. 2020

View full text Add to dashboard Cite

To investigate progression-free survival (PFS) and event-free survival (EFS) as early efficacy endpoints in diffuse large B-cell lymphoma (DLBCL), this systematic review included phase III randomized controlled trials (RCTs), phase II trials, and retrospective studies in newly diagnosed DLBCL receiving rituximab-containing chemotherapy through databases search up to 2019. Quality control was performed, where studies with high risk of bias were excluded. Prediction models were first established using the RCTs, and then externally validated in the phase II and retrospective populations. Trial-level surrogacy analysis was conducted by correlating the logarithmic (log) hazard ratio (HR) for PFS or EFS and log HR for OS. Correlation analysis at treatment arm-level was performed between 1-, 2-, 3-, and 5-year PFS or EFS rates and 5-year OS. The correlation was evaluated using the Pearson correlation coefficient r in weighted linear regression, with weight equal to patient size. Sensitivity analyses were performed to assess the consistency of predictive model by leaving one subgroup of trials out at a time. Twenty-six phase III RCTs, 4 phase II trials and 47 retrospective studies were included. In trial-level surrogacy, PFS (r, 0.772; 95% confidence interval [CI], 0.471–0.913) or EFS (r, 0.838; 95% CI, 0.625–0.938) were associated with OS. For rituximab immunochemotherapy treatment arms in RCTs, there was a linear correlation between 1 and 5-year PFS (r, 0.813–0.873) or EFS (r, 0.853–0.931) and 5-year OS. Sensitivity analysis demonstrated reasonable overall consistency. The correlation between PFS and OS was externally validated using independent phase II, and retrospective data (r, 0.795–0.897). We recommend PFS and EFS as earlier efficacy endpoints in patients with DLBCL primarily treated with rituximab-containing immunochemotherapy.

show abstract

“…A common method used to isolate CSCs is to utilize cell surface markers, including cluster of differentiation (CD) 90 and CD44, for isolation by flow cytometry (10). This was also the earliest reported method.…”

Section: Cell Surface Markersmentioning

confidence: 99%

“…Surgery, chemotherapy and radiotherapy are currently the main forms of cancer treatment; however, novel therapeutic approaches, including precision treatment (3), personalized therapy (4), molecular target therapy (5), complex immunologic therapy (6) and endocrine therapy (7,8), have also emerged. In addition, targeting cancer stem cells (CSCs) is an approach that has attracted an increasing amount of attention in cancer research, both in the lab and in clinical settings (9,10).…”

Section: Introductionmentioning

confidence: 99%

Cancer stem cells in esophageal squamous cell cancer (Review)

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are hypothesized to govern the origin, progression, drug resistance, recurrence and metastasis of human cancer. CSCs have been identified in nearly all types of human cancer, including esophageal squamous cell cancer (ESCC). Four major methods are typically used to isolate or enrich CSCs, including: i) fluorescence-activated cell sorting or magnetic-activated cell sorting using cell-specific surface markers; ii) stem cell markers, including aldehyde dehydrogenase 1 family member A1; iii) side population cell phenotype markers; and iv) microsphere culture methods. ESCC stem cells have been identified using a number of these methods. An increasing number of stem cell signatures and pathways have been identified, which have assisted in the clarification of molecular mechanisms that regulate the stemness of ESCC stem cells. Certain viruses, such as human papillomavirus and hepatitis B virus, are also considered to be important in the formation of CSCs, and there is a crosstalk between stemness and viruses-associated genes/pathways, which may suggest a potential therapeutic strategy for the eradication of CSCs. In the present review, findings are summarized along these lines of inquiry.

show abstract

Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

Cited by 35 publications

References 34 publications

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review

Cancer stem cells in esophageal squamous cell cancer (Review)

Contact Info

Product

Resources

About